Formerly known as Neurogene Technologies LLC, ArmaGen Technologies, Inc. is a biotechnology company developing therapies for severe neurological disorders. The company is advancing innovative therapies for the treatment of currently unaddressed neurological complications of lysosomal storage disorders (LSDs), as well as neurodegenerative diseases such as Alzheimers and Parkinsons. Most medications are unable to penetrate the blood-brain barrier (BBB) - creating a largely unmet medical need to treat neurological complications of many diseases, including LSDs and neurodegenerative diseases. ArmaGens pipeline is based on decades of work developing engineering therapies non-invasively to penetrate the BBB - a unique and dominant IP portfolio. Currently, ArmaGen has eight compounds in development: a lead product candidates are AGT-182 for Hunter syndrome, which is in Phase 1 clinical trials, and AGT-181 for Hurler syndrome, which is in Phase 2 trials.